@article{CCO13523,
author = {Priyanka Sharma},
title = {PARP inhibitor and platinum agent in triple negative breast cancer: utilizing innovative trial design to bring together something “new” and something “old”},
journal = {Chinese Clinical Oncology},
volume = {6},
number = {1},
year = {2017},
keywords = {},
abstract = {Triple negative breast cancer (TNBC) which is defined by the lack of expression of estrogen receptor (ER) and progesterone receptor (PgR), and absence of human epidermal growth factor receptor 2 (HER2) over expression and/or gene amplification accounts for approximately 15–20% of all breast cancers.},
issn = {2304-3873}, url = {https://cco.amegroups.org/article/view/13523}
}